Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma

Despite novel therapies for melanoma, drug resistance remains a significant hurdle to achieving optimal responses. NRAS‐mutant melanoma is an archetype of therapeutic challenges in the field, which we used to test drug combinations to avert drug resistance. We show that BET proteins are overexpresse...

Descripción completa

Detalles Bibliográficos
Autores principales: Echevarría‐Vargas, Ileabett M, Reyes‐Uribe, Patricia I, Guterres, Adam N, Yin, Xiangfan, Kossenkov, Andrew V, Liu, Qin, Zhang, Gao, Krepler, Clemens, Cheng, Chaoran, Wei, Zhi, Somasundaram, Rajasekharan, Karakousis, Giorgos, Xu, Wei, Morrissette, Jennifer JD, Lu, Yiling, Mills, Gordon B, Sullivan, Ryan J, Benchun, Miao, Frederick, Dennie T, Boland, Genevieve, Flaherty, Keith T, Weeraratna, Ashani T, Herlyn, Meenhard, Amaravadi, Ravi, Schuchter, Lynn M, Burd, Christin E, Aplin, Andrew E, Xu, Xiaowei, Villanueva, Jessie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938620/
https://www.ncbi.nlm.nih.gov/pubmed/29650805
http://dx.doi.org/10.15252/emmm.201708446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938620/
https://www.ncbi.nlm.nih.gov/pubmed/29650805
http://dx.doi.org/10.15252/emmm.201708446

Ejemplares similares